, Volume 106, Issue 1, pp 31–34 | Cite as

Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts

  • G. Lombardi
  • G. Gramegna
  • C. Cavanna
  • G. Poma
  • E. Marangoni
  • G. Michelone


Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans.

Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml).

Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.

Key words

amphotericin B itraconazole susceptibility testing yeast infections 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Medoff G, Brajtburg J, Kobayashi GS. Antifungal agents useful in therapy of systemic fungal infections. Ann Rev Pharmacol Toxicol 1983; 23: 303–30.Google Scholar
  2. 2.
    Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980; 302: 145–55.Google Scholar
  3. 3.
    Dismukes WE and NIAID Collaborative Mycoses Study Group. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and efficacy in 52 patients. Ann Intern Med 1973; 98: 13–20.Google Scholar
  4. 4.
    Cauwembergh C. Itraconazole: the first orally active antifungal for single day treatment of vaginal candidiasis. Curr Ther Res 1987; 41: 210–14.Google Scholar
  5. 5.
    Delescluses J, Cauwembergh G, Degreef H. Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor. Br J Dermatol 1986; 114: 701–3.Google Scholar
  6. 6.
    Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987; 9: S57-S63.Google Scholar
  7. 7.
    Negroni R, Palmieri O, Koren F, Tiraboschi IN, Galimberti RL. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis 1987; 9: S47-S50.Google Scholar
  8. 8.
    Restrepo A, Robledo J, Gomez I, Tabares AM, Gutierrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413–7.Google Scholar
  9. 9.
    Van Cutsem J, Van Gerven F, Van De Ven MA, Borgers M, Janssen PAJ. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984; 26: 527–34.Google Scholar
  10. 10.
    Lavalle P, Suchil P, De Ovando F, Reynoso S. Itraconazole for deep mycoses: preliminary experience in Mexico. Rev Infect Dis 1987; 9: S64-S70.Google Scholar
  11. 11.
    Sobel JD, Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob. Agents Chemother 1984; 26: 266–7.Google Scholar
  12. 12.
    Viviani MA, Tortorano AM, Giani PC, et al. Itraconazole for cryptococcal infection in the acquired immune deficiency syndrome. Ann Intern Med 1987; 106: 166.Google Scholar
  13. 13.
    De Gas J, Eeftinck Schattenkerk JKM, Van Ketel RJ. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J 1988; 296 (30 Jan): 339.Google Scholar
  14. 14.
    Perfect JR, Durack DT. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine and ketoconazole. J Infect Dis 1982; 146: 429–35.Google Scholar
  15. 15.
    Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob. Agents Chemother 1986; 29: 579–83.Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • G. Lombardi
    • 1
  • G. Gramegna
    • 1
  • C. Cavanna
    • 1
  • G. Poma
    • 1
  • E. Marangoni
    • 1
  • G. Michelone
    • 1
  1. 1.Istituto di Clinica delle Malattie InfettiveUniversità degli Studi di Pavia, IRCCS Policlinico S. MatteoPaviaItaly

Personalised recommendations